Riskpilot← Back to searchSign inGet full accessPHARMA NORGE AS
ASActiveOrg 919821590Sørvåg, 8432 AlsvågRetail sale of other food · NACE 4727Est. 201728 employees
Revenue 2024
NOK 55,2M
+36% vs 2023
EBITDA margin
28.2%
+84% vs 2023
Equity ratio
73.5%
Financial strength
Net profit 2024
NOK 14,2M
+109% vs 2023
| Revenue | NOK 55,2M | +36% |
| EBITDA | NOK 15,6M | +84% |
| Net profit | NOK 14,2M | +109% |
| Total assets | NOK 48,3M | +19% |
| Equity | NOK 35,5M | +9% |
| Employees | 28 | — |
Legal name
PHARMA NORGE AS
Org number
919821590
Legal form
Aksjeselskap
NACE code
4727 · Retail sale of other food
Founded
31. oktober 2017
Share capital
NOK 291 500
Employees
28 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder eller styrets leder hver for seg.
Company purpose
Detaljhandel med naturprodukter og helsekostprodukter samt investeringsaktivitet og deltakelse i andre selskaper.
Address
Sørvåg, 8432 Alsvåg
Phone
+4775803565
Email
post@l-serin.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 5 869 | 29 373 | 42 439 | 44 108 | 43 553 | 40 478 | 55 162 |
| Staff expenses | −513 | −3 940 | −6 585 | −8 094 | −9 656 | −9 581 | −9 965 |
| EBITDA | 490 | 8 117 | 15 031 | 13 837 | 13 347 | 8 481 | 15 580 |
| Depreciation & amort. | −0 | −8 | −130 | −177 | −190 | −106 | −123 |
| EBIT | 490 | 8 109 | 14 901 | 13 660 | 13 157 | 8 375 | 15 457 |
| Net financials | 0 | 13 | 129 | 23 | 27 | 370 | −71 |
| Profit before tax | 490 | 8 122 | 15 030 | 13 683 | 13 184 | 8 745 | 15 385 |
| Tax | 106 | 1 787 | 3 312 | 3 099 | 2 941 | 1 960 | 1 206 |
| Net profit | 384 | 6 335 | 11 717 | 10 584 | 10 244 | 6 785 | 14 179 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 1 668 | 5 581 | 11 329 | 13 334 | 40 396 | 40 405 | 48 251 |
| Equity | 233 | 1 384 | 2 701 | 5 068 | 30 804 | 32 469 | 35 483 |
| Long-term debt | 0 | 17 | 20 | 0 | 0 | 0 | 1 206 |
| Short-term debt | 1 435 | 4 180 | 8 608 | 8 265 | 9 593 | 7 936 | 11 562 |
| Total debt | 1 435 | 4 197 | 8 628 | 8 265 | 9 593 | 7 936 | 12 768 |
EBITDA margin
28.2%
This company
15.8%
Market median
+78% vs market
20182024
Equity ratio
73.5%
This company
38.2%
Market median
+92% vs market
20182024
Return on equity
40.0%
This company
18.4%
Market median
+117% vs market
20182024
Net profit margin
25.7%
This company
8.1%
Market median
+217% vs market
20182024
Asset turnover
1.14×
This company
1.12×
Market median
+2% vs market
20182024
Debt / equity
0.36×
This company
0.62×
Market median
+42% vs market
20182024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Global Pharma Group As | Company | 56.1% | 56.1% | 2024 |
| Individual | 7.8% | 7.8% | 2022 | |
Edutain As | Company | 7.0% | 7.0% | 2022 |
| Individual | 6.9% | 6.9% | 2024 | |
| Individual | 6.5% | 6.5% | 2024 | |
| Individual | 4.6% | 4.6% | 2024 | |
Sayl As | Company | 4.0% | 4.0% | 2024 |
Chima As | Company | 3.8% | 3.8% | 2024 |
Pharma Norge As | Company | 3.5% | 3.5% | 2024 |
| Individual | 3.0% | 3.0% | 2022 | |
Ps Capital As | Company | 3.0% | 3.0% | 2024 |
Storvestreinvest As | Company | 2.9% | 2.9% | 2024 |
Kjentfolk As | Company | 2.1% | 2.1% | 2022 |
Nobelsystem Scandinavia As | Company | 1.8% | 1.8% | 2024 |
Fun Invest As | Company | 1.7% | 1.7% | 2024 |
Infuture Invest As | Company | 1.6% | 1.6% | 2024 |
Storvestre Solutions As | Company | 1.4% | 1.4% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PHARMA NORGE AS (this company)
Nutripharma International AsBoard members of PHARMA NORGE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Svein Erik Nicolaysen | Chairman | 0 companies |
| Steffen Erland Eidal | Board of Directors | 0 companies |
| Thomas Kristoffer Storvestre | Chairman | 0 companies |
| Aasmund Olav Brevik | Board of Directors | 0 companies |